三维剪切波弹性成像评估HER-2阳性乳腺癌新辅助化疗疗效
该研究纳入43例HER-2阳性乳腺癌患者的43个病灶,在每周期新辅助化疗前行三维剪切波弹性成像(3D-SWE),测量病灶最大弹性硬度值(Emax)及其降低程度(ΔEmax)。以病理完全缓解(pCR)为金标准分组比较,发现Emax和ΔEmax对预测pCR具有一定价值,且随化疗周期增加预测准确性提高。
要点
- 3D-SWE测量的Emax和ΔEmax可预测HER-2阳性乳腺癌新辅助化疗的病理完全缓解。
- 化疗4周期后Emax≤30 kPa预测pCR的AUC达0.960,特异度92.5%,灵敏度88.9%。
- pCR组化疗前及每周期后Emax均低于非pCR组(P<0.05)。
核心结论
- 3D-SWE技术测量的Emax值和ΔEmax在评价HER-2阳性乳腺癌新辅助化疗疗效方面有一定预测价值。
研究设计与样本
- 选取2018年9月至2019年2月河南省人民医院经活检证实的HER-2阳性乳腺癌患者43例,共43个病灶。
- 每个化疗周期前行常规超声检查,在三维弹性和灰阶模式下选取感兴趣区,自动生成横切面、纵切面和冠状面剪切波数据。
- 以手术组织病理学结果为金标准,分为病理完全缓解组(pCR,18例)和非pCR组(25例)。
主要发现
- pCR组和非pCR组临床病理特征差异无统计学意义(均P>0.05)。
- 与新辅助化疗前比较,化疗期间pCR组和非pCR组Emax值均有不同程度降低,且pCR组化疗前和每周期后Emax值均小于非pCR组(均P<0.05)。
- 新辅助化疗1个周期后,Emax≤118 kPa为截断值时,预测pCR的特异度72.0%、灵敏度83.3%、AUC 0.838(95%CI 0.680~0.930)。
- 新辅助化疗4个周期后,Emax≤30 kPa为截断值时,预测pCR的特异度92.5%、灵敏度88.9%、AUC 0.960(95%CI 0.850~0.990)。
- 新辅助化疗4个周期后,ΔEmax以75.1%为截断值时,预测pCR的灵敏度72.3%、特异度92.0%、AUC 0.831(95%CI 0.690~0.930)。
关键数值与推荐
- 化疗1周期后Emax≤118 kPa预测pCR:特异度72.0%,灵敏度83.3%,AUC 0.838(95%CI 0.680~0.930)。
- 化疗2周期后Emax≤87 kPa预测pCR:特异度76.0%,灵敏度83.3%,AUC 0.863(95%CI 0.720~0.940)。
- 化疗3周期后Emax≤57 kPa预测pCR:特异度88.0%,灵敏度77.8%,AUC 0.893(95%CI 0.760~0.970)。
- 化疗1周期后ΔEmax以16.8%为截断值预测pCR:灵敏度88.0%,特异度60.0%,AUC 0.719(95%CI 0.620~0.890)。
- 化疗2周期后ΔEmax以34.9%为截断值预测pCR:灵敏度55.5%,特异度80.0%,AUC 0.712(95%CI 0.550~0.840)。
临床怎么用
- 对于HER-2阳性乳腺癌接受新辅助化疗的患者,可在每周期化疗前采用3D-SWE测量病灶Emax和ΔEmax。
- 依据不同化疗周期对应的Emax或ΔEmax截断值,辅助预测病理完全缓解,为疗效评估提供影像学参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinic value of ultrasound 3-dimensional shear wave elastography (3D-SWE) in therapeutic effect evaluation of neoadjuvant chemotherapy (NAC) for HER-2 positive breast cancer patients. Methods: A total of 43 lesions from 43 HER-2 positive breast cancer patients were selected and all of the lesions were confirmed by biopsy. Ultrasound examination was performed routinely before each chemotherapy cycle. The interested regions were selected under the 3-dimensional (3D) elasticity and gray-scale mode, the relevant data such as shear waves in the transverse, longitudinal and coronal sections of the mass were generated automatically. According to the histopathological results, the patients were divided into the pathological complete remission (pCR) group and the incomplete remission (non-pCR) group. The maximum elastic hardness value (Emax) and the reduction degree (ΔEmax) of the lesions in the two groups were measured and compared in each cycle of NAC. The accuracy of 3D-SWE technique for predicting the efficacy of NAC was evaluated using indicators such as sensitivity, specificity and area under the receiver operating characteristic (ROC) curve. Results: The clinicopathologic features between pCR group (18 cases) and non-pCR Group (25 cases) were not significantly different (P>0.05). Compared with pre-chemotherapy, the Emax values of pCR group and non-pCR Group during chemotherapy were declined (P<0.05). Moreover, the Emax values of pCR group before and after chemotherapy were lower than those of non-pCR group (P<0.05). At the end of the first cycle of chemotherapy, the predictive specificity, sensitivity and area under the curve (AUC) of pCR group were 72.0%, 83.3% and 0.838 (95%CI=0.680~0.930) respectively when the cutoff value of Emax was 118 kPa. At the end of the second cycle, the predictive specificity, sensitivity and AUC of pCR group were 76.0%, 83.3% and 0.863 (95%CI=0.720~0.940) respectively when the cutoff value of Emax was 87 kPa. At the end of the third cycle, the predictive specificity and sensitivity and the AUC of the pCR group were 88.0%, 77.8% and 0.893 (95%CI=0.760~0.970) when the cutoff value of Emax was 57 kPa. At the end of the fourth cycle of chemotherapy, the predictive specificity, sensitivity and AUC of pCR group were 92.5%, 88.9% and 0.960 (95%CI=0.850~0.990) respectively when the cutoff value of Emax was 30 kPa. After one cycle of NAC, the predictive sensitivity and specificity and AUC of pCR group were 88.0%, 60.0%, and 0.719 (95%CI=0.620~0.890) when the cutoff value of ΔEmax was 16.8%. After two cycles, the predictive sensitivity, specificity and AUC of pCR group were 55.5%, 80.0% and 0.712 (95%CI=0.550~0.840) when the cutoff value of ΔEmax was 34.9%. After three cycles, the predictive sensitivity, specificity and AUC of pCR group were 67.4%, 81.2% and 0.779 (95%CI=0.680~0.930) when the cutoff value of ΔEmax was 55.2%. After four cycles, the predictive sensitivity, specificity and AUC of pCR group was 72.3%, 92.0% and 0.831 (95%CI=0.690~0.930) when the cutoff value of ΔEmax was 75.1%. Conclusion: The Emax and ΔEmax values measured by 3D-SWE technology can predict the curative effect of NAC for breast cancer. 目的: 探讨超声三维剪切波弹性成像技术(3D-SWE)在人表皮生长因子受体2(HER-2)阳性乳腺癌患者新辅助化疗疗效评价中的应用价值。 方法: 选取2018年9月至2019年2月在河南省人民医院经活检穿刺证实为HER-2阳性的乳腺癌患者43例,共43个病灶。在每个化疗周期前均行常规超声检查,在三维弹性和灰阶模式下选取感兴趣区后,自动生成肿块的横切面、纵切面和冠状面的剪切波等相关数据。以手术组织病理学结果为金标准,分为病理完全缓解组(pCR)和非pCR组。测量并比较两组患者新辅助化疗各周期病灶最大弹性硬度值(Emax)及其降低程度(ΔEmax)。采用灵敏度、特异度和受试者工作特征曲线(ROC)的曲线下面积等指标评价3D-SWE技术预测新辅助化疗疗效的准确性。 结果: pCR组18例,非pCR组25例,pCR组和非pCR组乳腺癌患者的临床病理特征差异无统计学意义(均P>0.05)。与新辅助化疗前比较,化疗期间pCR组和非pCR组的Emax值均有不同程度的降低,且pCR组患者在化疗前和每个化疗周期后的Emax值均小于非pCR组(均P<0.05)。新辅助化疗1个周期后,当取Emax≤118 kPa为截断值时,预测pCR的特异度为72.0%,灵敏度为83.3%,曲线下面积为0.838(95%CI为0.680~0.930);2个周期后,当取Emax≤87 kPa为截断值时,预测pCR的特异度为76.0%,灵敏度为83.3%,曲线下面积为0.863(95%CI为0.720~0.940);3个周期后,当取Emax≤57 kPa为截断值时,预测pCR的特异度为88.0%,灵敏度为77.8%,曲线下面积为0.893(95%CI为0.760~0.970);4个周期后,当取Emax≤30 kPa为截断值时,预测pCR的特异度为92.5%,灵敏度为88.9%,曲线下面积为0.960(95%CI为0.850~0.990)。新辅助化疗1个周期后,ΔEmax以16.8%为截断值时,预测pCR的灵敏度为88.0%,特异度为60.0%,曲线下面积为0.719(95%CI为0.620~0.890);2个周期后,ΔEmax以34.9%为截断值时,预测pCR的灵敏度为55.5%,特异度为80.0%,曲线下面积为0.712(95%CI为0.550~0.840);3个周期后,ΔEmax以55.2%为截断值时,预测pCR的灵敏度为67.4%,特异度为81.2%,曲线下面积为0.779(95%CI为0.680~0.930);4个周期后,ΔEmax以75.1%为截断值时,预测pCR的灵敏度为72.3%,特异度为92.0%,曲线下面积为0.831(95%CI为0.690~0.930)。 结论: 3D-SWE技术测量乳腺癌病灶的Emax值和ΔEmax在评价乳腺癌新辅助化疗的疗效方面有一定的预测价值。.
引用
- Ma BX, Fan ZN, Wu G, et al. [The application of 3-dimensional shear wave elastography in the therapeutic effect evaluation of neoadjuvant chemotherapy for Her-2 positive breast cancer patients]. Zhonghua Zhong Liu Za Zhi. 2020. PMID: 33342163. doi:10.3760/cma.j.cn112152-20190828-00552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。